GLP-1 Medications and Muscle Loss (Sarcopenia): What to Know

What is GLP-1 muscle loss and why are people worried about it?

GLP-1 muscle loss refers to the reduction in lean (muscle) mass that happens alongside fat loss when people take GLP-1 medications such as semaglutide (Ozempic, Wegovy) and tirzepatide (Mounjaro). It is not unique to these drugs — losing some muscle is a near-universal feature of any large, rapid weight loss, whether from dieting, surgery or medication. The concern is whether GLP-1 medications, because they are so effective at driving weight down quickly, take too much muscle with the fat.

The worry is legitimate but often overstated in headlines. Across the evidence, the body still loses far more fat than muscle. A 2024–2025 network meta-analysis of 22 randomised trials (2,258 participants) found that lean mass loss was approximately 25% of the total weight loss — meaning roughly three-quarters of what comes off is fat Metabolism network meta-analysis, 2025. That is a meaningful amount of muscle to protect, but it is not the muscle-wasting collapse some coverage implies.

How much lean mass do you actually lose on Ozempic, Wegovy and Mounjaro?

The honest answer is that it varies by drug, dose and person — but the clearest single number comes from semaglutide's STEP 1 substudy. In that 68-week DXA analysis, total fat mass fell by 19.3% and total lean body mass fell by 9.7%; because fat fell faster, the proportion of the body made up of lean mass actually increased by about 3.0 percentage points STEP 1 body-composition substudy, 2021.

Looked at as a share of total weight lost, individual trials report a range. One review tabulated lean tissue as 39% of weight lost with semaglutide in STEP-1, 24% with tirzepatide, and 33% with retatrutide World Journal of Diabetes, 2025. These per-trial figures are higher than the pooled ~25% estimate above because they come from single studies measured in different ways — which is exactly why no one number tells the whole story.

For tirzepatide (Mounjaro), the SURMOUNT-1 trial found roughly 75% of weight loss from fat and 25% from lean mass, with reduced fat infiltration inside muscle and preserved fat-free muscle volume — a pattern suggesting muscle quality held up Cureus systematic review, 2025.

Is GLP-1 muscle loss the same as sarcopenia — and who is most at risk?

Not quite. Sarcopenia is a defined clinical condition — low muscle mass combined with low muscle strength or function — usually associated with ageing. Losing some lean mass on a GLP-1 is not automatically sarcopenia. But the two questions overlap, because the people most likely to be harmed by muscle loss are those who have the least muscle to spare.

Encouragingly, weight loss can sometimes improve the picture. In the SEMALEAN study of 106 patients on semaglutide over 12 months, lean mass fell by about 3.0kg up to month 7 and then stabilised — while handgrip strength rose by 4.1kg at 12 months and the prevalence of sarcopenic obesity fell from 49% to 33%, with 22% of initially sarcopenic patients no longer classified as sarcopenic by month 12 SEMALEAN study, 2026. Losing fat that was burdening the body can leave some people functionally stronger, even with slightly less muscle.

Older adults warrant particular care. An Annals of Internal Medicine editorial noted that GLP-1 treatment can account for a substantial share of fat-free mass loss (in the region of 30–35% of weight lost in some analyses), and that ageing itself reduces skeletal muscle by roughly 12–16% per decade in later life — so the two losses can stack Annals of Internal Medicine editorial, 2025. The takeaway is not to avoid treatment, but to be deliberate about protecting muscle if you are older or already low on it.

Why do GLP-1 medications cause lean mass loss in the first place?

The lean-mass loss is mostly a consequence of rapid weight loss, not a direct muscle toxin. When the body sheds weight quickly, several things happen together that lower muscle:

• Large energy deficit — strong appetite suppression means you eat much less, and the body draws on both fat and muscle to make up the shortfall.
• Lower protein intake — eating less overall often means eating less protein, the raw material muscle needs to maintain itself.
• Reduced mechanical load — as weight drops, muscles do less work carrying the body, and unused muscle is signalled to shrink.

This matters because it means the muscle loss is largely modifiable. The same evidence that flags the risk also points to the fix: maintain the protein and the loading, and you keep more of the muscle. It is a problem of inputs, not an unavoidable side effect.

What is the link between muscle loss and bone loss on GLP-1 medications?

Muscle and bone are biologically linked, and rapid weight loss tends to reduce both together — though it's important to be clear about what the muscle studies here do and don't show. None of the body-composition studies cited above measured bone, so any muscle-to-bone claim has to be made carefully.

What is well established more broadly is that muscle and bone work as a unit: the pull of muscle on the skeleton is one of the signals that keeps bone remodelling healthy, and large weight loss reduces both lean mass and the load placed through bone at the same time. Early evidence suggests that the conditions which drive muscle loss on a GLP-1 — a big energy deficit, lower protein, less loading — are the same conditions associated with falling bone density during weight loss.

For the detail on what the bone-specific research actually shows, see our companion guide: Do Ozempic and weight-loss injections cause bone loss?. The practical point for muscle is that protecting one tends to protect the other, which is why the prevention advice below is good for your skeleton as well as your muscles.

Can resistance training and protein prevent muscle loss on GLP-1s?

Yes — the strongest, most consistent message across the evidence is that resistance (strength) training plus adequate protein protects lean mass during weight loss. Aerobic exercise alone is not enough; it is the strength work that does the heavy lifting for muscle.

One narrative review framed the approach as a combined programme: meet general activity targets of 150 minutes of moderate-intensity or 75 minutes of vigorous aerobic activity per week, plus 60–90 minutes of resistance training weekly, noting that resistance training specifically attenuates lean body mass loss Frontiers in Clinical Diabetes and Healthcare, 2025. A separate review reported that resistance exercise can reduce fat-free mass loss by 50–95% during calorie restriction, and recommended a protein target of around 1.5g per kg of body weight per day World Journal of Diabetes, 2025.

In practice, that means:

• Resistance training (weights, bands, bodyweight) several times a week to give muscle a reason to stay.
• Protein at every meal, aiming toward the ~1.5g/kg/day mark unless your clinician advises otherwise.
• Keeping muscle matters for the long run too — the same Frontiers review noted patients can regain up to two-thirds of lost weight within a year of stopping, and more muscle supports a higher metabolic rate.

These habits protect bone as well as muscle, which is the recurring theme of this series.

What should you monitor — and how — if you are on a GLP-1 in the UK?

Because muscle and bone can change quietly during rapid weight loss, the single most useful step is to establish a baseline and track from there. At present there is no routine programme that monitors muscle or bone change for people on weight-loss injections, so it largely falls to the individual to keep an eye on body composition over a one- to two-year course.

A baseline assessment answers the question that matters: is my body composition changing in a way I should act on? Catching change early — while weight is still coming off — is exactly when it is easiest to respond with more strength training and protein.

Why a radiation-free REMS scan suits repeat monitoring

Because muscle loss and bone loss tend to travel together during weight loss, tracking bone density is a practical, measurable proxy for whether your skeleton is keeping up. Standard DEXA scans use a small dose of X-ray radiation, which makes frequent re-scanning less ideal. REMS (Radiofrequency Echographic Multi Spectrometry) is radiation-free, so it can be safely repeated across a long GLP-1 course to monitor change over time.

You can book a radiation-free bone health assessment, read more about our bone health assessment, or see where we screen across the UK.

The bottom line on GLP-1s and muscle

GLP-1 medications cause some muscle loss — typically around a quarter of total weight lost — but the body sheds far more fat, and the loss is largely modifiable. Resistance training and enough protein are the proven defences, and because muscle and bone change together, monitoring your bone health gives you an early, measurable read on how your body is holding up. The aim is simple: lose the fat, keep the muscle, and protect the bone underneath it.

---

This article is part of our weight-loss medications and bone health series. For the bone-specific evidence, see Do Ozempic and weight-loss injections cause bone loss?; for more on protecting muscle as you age, see our muscle health and sarcopenia guides.